Clinical experience on EGFR tyrosine kinase inhibitor in non-small cell lung cancer, compassionate programme in Czech Republic

被引：0
|
作者：
Pesek, M.
Skrickova, J.
Kolek, V.
Zatloukal, P.
Petruzelka, L.
Svobodnik, A.
机构：
[1] Fac Med, Dept TB & Pulm Dis, Plzen, Czech Republic
[2] Fac Med, Dept TB & Pulm Dis, Brno, Czech Republic
[3] Fac Med, Dept TB & Pulm Dis, Olomouc, Czech Republic
[4] Fac Med, Dept Pneumol & Thorac Surg, Prague 8, Czech Republic
[5] Fac Med, Dept Oncol Dis, Prague 2, Czech Republic
[6] Masaryk Univ, Ctr Biostat & Anal, Brno, Czech Republic
来源：
LUNG CANCER | 2006年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [41] Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer
    Ding, Q.
    Shao, Y.
    Wu, X.
    Hu, Q.
    Meng, Q.
    Yin, J. C.
    Ou, Q.
    Wu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S580 - S580
  • [42] Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone, Alfredo
    Lerose, Rosa
    Lazzari, Chiara
    Gregorc, Vanesa
    Aieta, Michele
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [43] Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
    Ohtaki, Yoichi
    Shimizu, Kimihiro
    Suzuki, Hiroyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Mitsudomi, Tetsuya
    Takao, Motoshi
    Murakawa, Tomohiro
    Ito, Hiroyuki
    Yoshimura, Kenichi
    Okada, Morihito
    Chida, Masayuki
    LUNG CANCER, 2021, 153 : 108 - 116
  • [44] Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
    Poon, Candice C.
    Kelly, John J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 1945 - 1954
  • [45] The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
    Nikolinakos, Petros
    Heymach, John V.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S131 - S134
  • [46] Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy
    Watanabe, S.
    Saida, Y.
    Ichikawa, K.
    Koshio, J.
    Baba, J.
    Miura, S.
    Tanaka, J.
    Kagamu, H.
    Narita, I.
    Yoshizawa, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S618 - S619
  • [47] Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    de Bruin, Elza C.
    Cowell, Catherine F.
    Howell, Michael
    Varmus, Harold E.
    Politi, Katerina
    Downward, Julian
    CANCER RESEARCH, 2011, 71
  • [48] Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Min Jae
    Yi, Jun Ho
    Kim, Tae Sung
    Chung, Myung Jin
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    LUNG CANCER, 2010, 69 (01) : 105 - 109
  • [49] Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Wang, Hui
    Hu, Qianfan
    Chen, Yuzhong
    Huang, Xing
    Feng, Yipeng
    Shi, Yuanjian
    Li, Rutao
    Yin, Xuewen
    Song, Xuming
    Liang, Yingkuan
    Zhang, Te
    Xu, Lin
    Dong, Gaochao
    Jiang, Feng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [50] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
12345